Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.

Following a filing revealing its intent to go public in the US on 6 January, artificial pancreas maker Beta Bionics has now ...

JMP Securities analyst reaffirmed a positive outlook on Larimar Therapeutics (NASDAQ:LRMR), maintaining a Market Outperform ...

Shares of Ionis Pharmaceuticals (NASDAQ:IONS) climbed 7% today after the company announced that regulatory agencies in the ...

Discover the potential of Ispire's innovative cannabis products and holistic solutions, a hidden gem in a competitive market with room to grow.

The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

As the percentage of the global population over 65 continues to increase, the popularity of anti-aging stocks is rising in tandem thanks to advancements in technology and a growing body of research on ...

Sandip Kapadia, the Chief Financial Officer of Harmony Biosciences Holdings , Inc. (NASDAQ:HRMY), a pharmaceutical company ...

Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than ...

Andrew Dudum, the Chief Executive Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently executed a series of stock transactions, according to a Form 4 filing with the Securities and Exchange ...